The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma
Open accessAbstract
Summ a r yAntigen-driven selection has been implicated in the pathogenesis of monoclonal gammopathies.Patients with Gaucher's disease have an increased risk of monoclonal gammopathies.Here we show that the clonal immunoglobulin in patients with Gaucher's disease and in mouse models of Gaucher's disease-associated gammopathy is reactive against lyso-glucosylceramide (LGL1), which is markedly elevated in these patients and mice.Clonal immunoglobulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolipids LGL1 and lysophosphatidylcholine (LPC).Substrate reduction ameliorates Gaucher's disease-associated gammopathy in mice.Thus, longterm immune activation by lysolipids may underlie both Gaucher's disease-associated gammopathies and some sporadic monoclonal gammopathies.M ultiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) are characterized by clonal expansion of transformed plasma cells. 1 Analyses of immunoglobulin genes in tumor cells have provided evidence of antigen-driven selection, with restricted heavy-chain variableregion use and highly hypermutated immunoglobulin heavy-and light-chain genes. [2][3]][4][5][6] However, the antigens underlying the origins of most MGUS and myeloma clones remain unknown.Hyperphosphorylated modification of stomatin (EPB72)-like 2 protein (STOML2, which is identical to paratarg-7) due to the inactivation of protein phosphatase 2A was identified as a target of certain paraproteins and an inherited risk factor for the development of gammopathies.[7][8][9] A recent study identified sumoylated heat-shock protein 90 as another inherited risk factor for plasma-cell dyscrasia.10 However, there remains a need to identify the antigenic origins of MGUS and myeloma that may be amenable to targeted prevention.Lipids (such as pristane) were implicated in the earliest models of murine plasmacytoma, 11 and lipid disorders such as Gaucher's disease and obesity are associated with an increased risk of myeloma.12,13 The risk of myeloma is markedly higher among patients with Gaucher's disease, in whom myeloma is now emerging as a leading cause of cancer-related death, than in the general population.13 Glucocerebrosidase deficiency in Gaucher's disease leads to increases in the level of LGL1.14 Recently, we identified a subset of human and murine LGL1-specific CD1d-restricted type 2 natural killer T cells that constitutively expressed markers of follicular helper T cells and helped in the differentiation of lipid-reactive plasma cells.15 In an earlier study, we found an elevation of type 2 natural killer T cells against another bioactive lysolipid, LPC, in myeloma.16 These studies led us to test whether the clonal immunoglobulin in Gaucher's disease-associated myeloma and sporadic myeloma was reactive against LGL1 and LPC. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, several studies have supported the idea that the B-cells from which MM originate, experience a prolonged/chronic stimulation in the GC.15,40,41,70,71”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This idea of chronic stimulation or B-cells re-entering has found robust evidence in the Gaucher disease where the chronic stimulation of B-cells against lyso-glucosylceramide (LGL1) promotes the development of MGUS with clonal immunoglobulin specific for LGL1.40,41”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, it has also been demonstrated that patients exposed to certain agents (e.g. Agent Orange in Vietnam veterans, pesticides in agricultural worker, or 9/11 World Trade Center dust in first responders) or those suffering from specific conditions (such as HIV or Gaucher) have a higher prevalence of these clonal populations. 37-39 40,41 42”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Pietiläinen, K. H., Sysi‐Aho, M., Rissanen, A., Seppänen‐Laakso, T., Yki‐Järvinen, H., Kaprio, J. A., & Orešič, M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000218 · Cited by 418
Bakkus, M. H. C., Heirman, C., Riet, I. V., Camp, B. V., & Thielemans, K. (1992) · Blood · doi:10.1182/blood.v80.9.2326.2326 · Cited by 315
Dekker, N., van Dussen, L., Hollak, C., Overkleeft, H., Scheij, S., Ghauharali, K., van Breemen, M. V., Ferraz, M. J., Groener, J., Maas, M., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352971 · Cited by 277
Self-citationMistry, P. K., Liu, J., Yang, M., Nottoli, T., McGrath, J. M., Jain, D., Zhang, K., Keutzer, J. M., Chuang, W., Mehal, W. Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003308107 · Cited by 244
Self-citationInduction of Plasma Cell Tumours in BALB/c Mice with 2,6,10,14-Tetramethylpentadecane (Pristane)
ANDERSON, P. N., & Potter, M. (1969) · Nature · doi:10.1038/222994a0 · Cited by 192
Landgren, O., Rajkumar, S. V., Pfeiffer, R. M., Kyle, R. A., Katzmann, J. A., Dispenzieri, A. A., Cai, Q., Goldin, L. R., Caporaso, N. E., Fraumeni, J. F., et al. (2010) · Blood · doi:10.1182/blood-2010-01-262394 · Cited by 165
Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1
Mistry, P. K., Lukina, E., Turkia, H. B., Amato, D., Baris, H. N., Dasouki, M., Ghosn, M. G., Mehta, A. B., Packman, S., Pastores, G. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.459 · Cited by 156
Self-citationInflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer
Chang, D., Deng, H., Matthews, P., Krasovsky, J., Ragupathi, G., Špíšek, R., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2008) · Blood · doi:10.1182/blood-2008-04-149831 · Cited by 143
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Sphingolipid metabolism in cancer signalling and therapy
Ogretmen, B. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.96 · Cited by 1,207
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, J., Froissart, R., Caillaud, C., Levade, T., Astudillo, L. M., Serratrice, J., Brassier, A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020441 · Cited by 914
Natural Killer T Cells in Cancer Immunotherapy
Nair, S., & Dhodapkar, M. V. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01178 · Cited by 231
Self-citationLysosomal storage disorders – challenges, concepts and avenues for therapy: beyond rare diseases
Marques, A. R. A., & Säftig, P. (2019) · Journal of Cell Science · doi:10.1242/jcs.221739 · Cited by 233
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S. N., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 212
Gaucher Disease in Bone: From Pathophysiology to Practice
Hughes, D. A., Mikosch, P., Belmatoug, N., Carubbi, F., Cox, T., Göker-Alpan, Ö., Kindmark, A., Mistry, P. K., Poll, L. W., Weinreb, N. J., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3734 · Cited by 203
Self-citationGlucosylsphingosine is a key biomarker of Gaucher disease
Murugesan, V., Chuang, W., Liu, J., Lischuk, A. W., Kacena, K. A., Lin, H., Pastores, G. M., Yang, R., Keutzer, J. M., Zhang, K., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24491 · Cited by 195
Self-citationComplement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease
Pandey, M. K., Burrow, T. A., Rani, R., Martin, L. J., Witte, D. P., Setchell, K. D. R., McKay, M. A., Magnusen, A. F., Zhang, W., Liou, B., et al. (2017) · Nature · doi:10.1038/nature21368 · Cited by 193
MGUS to myeloma: a mysterious gammopathy of underexplored significance
Dhodapkar, M. V. (2016) · Blood · doi:10.1182/blood-2016-09-692954 · Cited by 179
Self-citationGaucher disease: Progress and ongoing challenges
Mistry, P. K., Lopez, G. J., Schiffmann, R., Barton, N. W., Weinreb, N. J., & Sidransky, E. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.11.006 · Cited by 175
Self-citationCell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 184
Timing the Initiation of Multiple Myeloma
Rustad, E. H., Yellapantula, V., Leongamornlert, D., Bolli, N., Ledergor, G., Nadeu, F., Angelopoulos, N., Dawson, K. J., Mitchell, T. J., Osborne, R. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15740-9 · Cited by 165
Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice
Das, R., Strowig, T., Verma, R., Koduru, S. V., Hafemann, A., Hopf, S., Kocoglu, M. H., Borsotti, C., Zhang, L., Branagan, A. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4202 · Cited by 162
Self-citationHao, J., Zhang, Y., Yan, X., Yan, F., Sun, Y., Zeng, J., Waigel, S. J., Yin, Y., Fraig, M., Egilmez, N. K., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.006 · Cited by 159
Type II NKT Cells and Their Emerging Role in Health and Disease
Dhodapkar, M. V., & Kumar, V. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601399 · Cited by 150
Self-citationRecent advances in the diagnosis and management of Gaucher disease
Gary, S. E., Ryan, E., Steward, A., & Sidransky, E. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1445524 · Cited by 143
Precancer Atlas to Drive Precision Prevention Trials
Spira, A. E., Yurgelun, M. B. B., Alexandrov, L. B., Rao, A., Bejar, R., Polyák, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2346 · Cited by 134
Self-citationPanaroni, C., Fulzele, K. S., Mori, T., Siu, K. T., Onyewadume, C., Maebius, A., & Raje, N. S. (2021) · Blood · doi:10.1182/blood.2021013832 · Cited by 118
Cassiman, D. M., Packman, S., Bembi, B., Turkia, H. B., Al‐Sayed, M., Schiff, M., Imrie, J., Mabe, P., Takahashi, T., Mengel, K. E., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.05.001 · Cited by 116
Glucocerebrosidase: Functions in and Beyond the Lysosome
Boer, D. E. C., van Smeden, J., Bouwstra, J. A., & Aerts, J. M. F. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030736 · Cited by 105
Inflammation and aging-related disease: A transdisciplinary inflammaging framework
Andonian, B. J., Hippensteel, J. A., Abuabara, K., Boyle, E. M., Colbert, J. F., Devinney, M. J., Faye, A. S., Kochar, B. D., Lee, J., Litke, R. R., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01364-0 · Cited by 109
Mistry, P. K., Lukina, E., Turkia, H. B., Shankar, S. P., Baris, H. N., Ghosn, M. G., Mehta, A. B., Packman, S., Pastores, G. M., Petakov, M. S., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24877 · Cited by 97
Self-citationRevel‐Vilk, S., Fuller, M., & Zimran, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197159 · Cited by 97
Mechanisms of Ceramide-Dependent Cancer Cell Death
Nganga, R., Oleinik, N. V., & Öğretmen, B. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.04.007 · Cited by 92
Wei, X., Calvo-Vidal, M. N., Chen, S., Wu, G., Revuelta, M. V., Sun, J. H., Zhang, J., Walsh, M. F., Nichols, K. E., Vijai, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1900 · Cited by 87
Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells
Falank, C. R., Fairfield, H. E., & Reagan, M. R. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00067 · Cited by 86
Van der Lienden, M. J. C., Gaspar, P., Boot, R., Aerts, J. M. F. G., & Van Eijk, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010066 · Cited by 84
Panaroni, C., Yee, A. J., & Raje, N. S. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0397-5 · Cited by 82
Exploring genetic modifiers of Gaucher disease: The next horizon
Davidson, B. A., Hassan, S., Garcia, E. J., Tayebi, N., & Sidransky, E. (2018) · Human Mutation · doi:10.1002/humu.23611 · Cited by 79
Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function
Kim, M. J., Jeon, S., Burbulla, L. F., & Krainc, D. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy105 · Cited by 77
Lukina, E., Watman, N. P., Dragosky, M. O., Lau, H., Arreguin, E. Á., Rosenbaum, H., Zimran, A., Foster, M. C., Gaemers, S. J. M., & Peterschmitt, M. (2018) · American Journal of Hematology · doi:10.1002/ajh.25300 · Cited by 74
Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease
Aerts, J. M. F. G., Kuo, C. J., Lelieveld, L. T., Boer, D. E. C., van der Lienden, M. J. C., Overkleeft, H. S., & Artola, M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.10.006 · Cited by 71
Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment
Janneh, A. H., & Öğretmen, B. (2022) · Cancers · doi:10.3390/cancers14092183 · Cited by 69
Checkpoint Inhibition in Myeloma: Opportunities and Challenges
Costa, F., Das, R., Bailur, J. K., Dhodapkar, K. M., & Dhodapkar, M. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02204 · Cited by 66
Self-citationLeveraging premalignant biology for immune-based cancer prevention
Spira, A. E., Disis, M. L., Schiller, J. T., Vilar, E., Rebbeck, T. R., Bejar, R. L., Ideker, T., Arts, J., Yurgelun, M. B. B., Mesirov, J. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608077113 · Cited by 64
The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
Lopes, R., Caetano, J., Ferreira, B. V., Barahona, F., Carneiro, E. A., & Joao, C. M. (2021) · Cancers · doi:10.3390/cancers13040625 · Cited by 64
Antigen-mediated regulation in monoclonal gammopathies and myeloma
Nair, S., Sng, J., Boddupalli, C. S., Seckinger, A., Chesi, M., Fulciniti, M., Zhang, L., Rauniyar, N., Lopez, M., Neparidze, N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98259 · Cited by 60
Self-citationLyso-glycosphingolipids: presence and consequences
van Eijk, M., Ferraz, M. J., Boot, R. G., & Aerts, J. M. F. G. (2020) · Essays in Biochemistry · doi:10.1042/ebc20190090 · Cited by 59
Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
Giuffrida, G., Markovic, U., Condorelli, A., Calafiore, V., Nicolosi, D., Calagna, M., Grasso, S., Ragusa, M. T. V., Gentile, J., & Napolitano, M. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02623-7 · Cited by 62
Sykes, D. B., O'Connell, C. L., & Schroyens, W. (2020) · Blood · doi:10.1182/blood.2019004216 · Cited by 54
Boddupalli, C. S., Nair, S., Belinsky, G. S., Gans, J., Teeple, E. A., Nguyen, T., Mehta, S. S., Guo, L., Kramer, M. L., Ruan, J., et al. (2022) · eLife · doi:10.7554/elife.79830 · Cited by 56
Self-citationWang, Q., Shi, Q., Lu, J., Wang, Z., & Hou, J. (2022) · International Journal of Cancer · doi:10.1002/ijc.34214 · Cited by 51
La maladie de Gaucher : quand y penser ?
Nguyen, Y., Stirnemann, J., & Belmatoug, N. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.11.012 · Cited by 54
An unexpected player in Gaucher disease: The multiple roles of complement in disease development
Pandey, M. K., Grabowski, G. A., & Köhl, J. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.006 · Cited by 49
Glycosphingolipids and Infection. Potential New Therapeutic Avenues
Aerts, J. M. F. G., Artola, M., van Eijk, M., Ferraz, M. J., & Boot, R. G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00324 · Cited by 49
Bosseboeuf, A., Allain‐Maillet, S., Mennesson, N., Tallet, A., Rossi, C., Garderet, L., Caillot, D., Moreau, P., Piver, É., Girodon, F., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01347 · Cited by 46
Mistry, P. K., Lukina, E., Turkia, H. B., Shankar, S. P., Feldman, H. B., Ghosn, M. G., Mehta, A. B., Packman, S., Lau, H., Petakov, M. S., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26276 · Cited by 46
Self-citationMonoclonal IgG in MGUS and multiple myeloma targets infectious pathogens
Bosseboeuf, A., Féron, D., Tallet, A., Rossi, C., Charlier, C., Garderet, L., Caillot, D., Moreau, P., Cardó‐Vila, M., Pasqualini, R., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.95367 · Cited by 45
Monoclonal Gammopathy of Undetermined Significance
Gonsalves, W. I., & Rajkumar, S. V. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202212200 · Cited by 44
Nair, S., Bar, N., Xu, M. L., Dhodapkar, M. V., & Mistry, P. K. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.01.009 · Cited by 44
Self-citationRosenbloom, B. E., Cappellini, M. D., Weinreb, N. J., Dragosky, M. O., Revel‐Vilk, S., Batista, J. L., Sekulić, D., & Mistry, P. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26675 · Cited by 41
Self-citationGlucosylsphingosine is a reliable response biomarker in G aucher disease
Arkadir, D., Dinur, T., Revel‐Vilk, S., Becker‐Cohen, M., Cozma, C., Hovakimyan, M., Eichler, S., Rolfs, A., & Zimran, A. (2018) · American Journal of Hematology · doi:10.1002/ajh.25074 · Cited by 41
Interstitial lung disease in lysosomal storage disorders
Borie, R., Crestani, B., Guyard, A., & Lidove, O. (2021) · European Respiratory Review · doi:10.1183/16000617.0363-2020 · Cited by 41
Halade, G. V., Black, L. M., & Verma, M. K. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.02.014 · Cited by 42
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
Lesokhin, A. M., Bal, S., & Badros, A. Z. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0148 · Cited by 40
Dhodapkar, M. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26752 · Cited by 41
Self-citationPandey, M. K. (2023) · Biomedicines · doi:10.3390/biomedicines11041067 · Cited by 40
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
Caro, J., Braunstein, M. J., Williams, L. S., Bruno, B., Kaminetzky, D., Siegel, A., Razzo, B. M., Alfandari, S., Morgan, G. J., Davies, F. E., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01506-9 · Cited by 39
C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages
Serfecz, J. C., Saadin, A., Santiago, C. P., Zhang, Y., Bentzen, S. M., Vogel, S. N., & Feldman, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189912 · Cited by 36
Lelieveld, L. T., Mirzaian, M., Kuo, C. J., Artola, M., Ferraz, M. J., Peter, R. E. A., Akiyama, H., Greimel, P., van den Berg, R. J. B. H. N., Overkleeft, H. S., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.ra119000154 · Cited by 37
Wątek, M., Piktel, E., Wollny, T., Durnaś, B., Fiedoruk, K., Lech‐Marańda, E., & Bucki, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040843 · Cited by 32
Monoclonal gammopathy of undetermined significance
Rajkumar, S. V., & Kumar, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412716 · Cited by 31
Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
Mistry, P. K., Balwani, M., Barbouth, D., Burrow, T. A., Ginns, E. I., Göker-Alpan, Ö., Grabowski, G. A., Kartha, R. V., Kishnani, P. S., Lau, H., et al. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.05.002 · Cited by 31
Self-citationMonoclonal immunoglobulins promote bone loss in multiple myeloma
Westhrin, M., Kovcic, V., Zhang, Z., Moen, S. H., Nedal, T. M. V., Bondt, A., Holst, S., Misund, K., Buene, G., Sundan, A., et al. (2020) · Blood · doi:10.1182/blood.2020006045 · Cited by 31
Hematological manifestations and complications of Gaucher disease
Revel‐Vilk, S., Szer, J., & Zimran, A. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1908120 · Cited by 31
Mutations, inflammation and phenotype of myeloproliferative neoplasms
Hermouet, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1196817 · Cited by 31
Lidove, O., Belmatoug, N., Froissart, R., Lavigne, C., Durieu, I., Mazodier, K., Serratrice, J., Douillard, C., Goizet, C., Cathébras, P. J., et al. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.10.387 · Cited by 30
Allegra, A., Innao, V., Allegra, A. G., Pugliese, M., Salvo, E. D., Ventura-Spagnolo, E., Musolino, C., & Gangemi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112822 · Cited by 30
HLA polymorphism and risk of multiple myeloma
Beksaç, M., Gragert, L. A., Fingerson, S., Maiers, M. J., Zhang, M.-J., Albrecht, M. C., Zhong, X., Cozen, W., Dispenzieri, A. A., Lonial, S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.199 · Cited by 28
Dubot, P., Astudillo, L. M., Therville, N., Sabourdy, F., Stirnemann, J., Levade, T., & Andrieu‐Abadie, N. (2020) · Cancers · doi:10.3390/cancers12020475 · Cited by 32
Allain‐Maillet, S., Bosseboeuf, A., Mennesson, N., Bostoën, M., Dufeu, L., Choi, E. H. E., Cleyrat, C., Mansier, O., Lippert, É., Bris, Y. L., et al. (2020) · Cancers · doi:10.3390/cancers12092446 · Cited by 29
Andrade‐Campos, M., de Frutos, L. L., Cebolla, J. J., Serrano‐Gonzalo, I., Medrano-Engay, B., Roca‐Espiau, M., Gomez-Barrera, B., Pérez-Heredia, J., Íñiguez, D., & Giraldo, P. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01520-7 · Cited by 28
Serratrice, J., Carballo, S., Serratrice, J., & Stirnemann, J. (2016) · Core evidence · doi:10.2147/ce.s93717 · Cited by 28
Carubbi, F., Cappellini, M. D., Fargion, S. R., Fracanzani, A. L., & Nascimbeni, F. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.01.004 · Cited by 31
Patients with Gaucher disease display systemic oxidative stress dependent on therapy status
Kartha, R. V., Terluk, M. R., Brown, R. Z., Travis, A., Mishra, U. R., Rudser, K. D., Lau, H., Jarnes, J. R., Cloyd, J. C., & Weinreb, N. J. (2020) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2020.100667 · Cited by 27
Maura, F., Landgren, O., & Morgan, G. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1395 · Cited by 28
Role of Specific B-Cell Receptor Antigens in Lymphomagenesis
Thurner, L., Hartmann, S., Neumann, F., Hoth, M., Stilgenbauer, S., Küppers, R., Preuss, K., & Bewarder, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.604685 · Cited by 26
Mehdi, S. J., Johnson, S., Epstein, J., Zangari, M., Qu, P., Hoering, A., van Rhee, F., Schinke, C., Thanendrarajan, S., Barlogie, B., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15669 · Cited by 24
Nguyen, Y., Stirnemann, J., Lautredoux, F., Cador, B., Bengherbia, M., Yousfi, K., Hamroun, D., Astudillo, L. M., de Villemeur, T. B., Brassier, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041247 · Cited by 24
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
Vià, M. D., Ziccheddu, B., Maeda, A., Bagnoli, F., Perrone, G., & Bolli, N. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000502 · Cited by 27
Activity-Based Probes for Glycosidases: Profiling and Other Applications
Kuo, C. J., van Meel, E., Kytidou, K., Kallemeijn, W. W., Witte, M. D., Overkleeft, H. S., Artola, M., & Aerts, J. M. F. G. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.06.039 · Cited by 23
TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
Ivanova, M. M., Dao, J., Noll, L., Fikry, J., & Göker-Alpan, Ö. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102217 · Cited by 23
Leng, H., Zhang, H., Li, L., Zhang, S., Wang, Y., Chavda, S. J., Galas‐Filipowicz, D., Lou, H., Ersek, A., Morris, E. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35358-3 · Cited by 23
Choa, R., Panaroni, C., Bhatia, R., & Raje, N. S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010822 · Cited by 23
Weinreb, N. J., Mistry, P. K., Rosenbloom, B. E., & Dhodapkar, M. V. (2018) · Blood · doi:10.1182/blood-2018-02-834689 · Cited by 21
Self-citationTreatment of Patients with Monoclonal Gammopathy of Clinical Significance
Moreno, D. F., Rosiñol, L., Cibeira, M. T., Bladé, J., & de Larrea, C. F. (2021) · Cancers · doi:10.3390/cancers13205131 · Cited by 20
Dupuis, L., Chauvet, M., Bourdelier, E., Dussiot, M., Belmatoug, N., Kim, C. L. V., Chêne, A., & Franco, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147640 · Cited by 20
Kato, S., Berzofsky, J. A., & Terabe, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00314 · Cited by 23
Allegra, A., Innao, V., Gerace, D. G., Allegra, A. G., Vaddinelli, D., Bianco, O., & Musolino, C. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.033 · Cited by 21
Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
McCachren, S. S., Dhodapkar, K. M., & Dhodapkar, M. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632564 · Cited by 21
Self-citationNovel Management and Screening Approaches for Haematological Complications of Gaucher’s Disease
Giraldo, P., & Andrade-Campos, M. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s279756 · Cited by 19
Cox, T. M., Charrow, J., Lukina, E., Mistry, P. K., Foster, M. C., & Peterschmitt, M. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.10.011 · Cited by 19
Self-citationTomasson, M. H., Ali, M., Oliveira, V. D., Xiao, Q., Jethava, Y. S., Zhan, F., Fitzsimmons, A. M., & Bates, M. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113621 · Cited by 21
Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance
Georgakopoulou, R., Andrikopoulou, Α., Sergentanis, T. Ν., Fiste, O., Zagouri, F., Gavriatopoulou, M., Ψαλτοπούλου, Θ., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.01.008 · Cited by 19
Malignant T Cell Activation by a Bacillus Species Isolated from Cutaneous T-Cell Lymphoma Lesions
Dehner, C. A., Ruff, W. E., Greiling, T. M., Pereira, M. S., Redanz, S., McNiff, J. M., Girardi, M., & Kriegel, M. A. (2021) · JID Innovations · doi:10.1016/j.xjidi.2021.100084 · Cited by 19
van Meel, E., Bos, E., van der Lienden, M. J. C., Overkleeft, H. S., van Kasteren, S. I., Koster, A. J., & Aerts, J. M. F. G. (2019) · Traffic · doi:10.1111/tra.12641 · Cited by 19
The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges
Lazaris, V., Hatziri, A., Symeonidis, A. S., & Kypreos, K. E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638288 · Cited by 19
A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact
Zimran, A., Ruchlemer, R., & Revel‐Vilk, S. (2020) · Hematology · doi:10.1182/hematology.2020000123 · Cited by 17
Challenges in Gaucher disease: Perspectives from an expert panel
Grabowski, G. A., Kishnani, P. S., Alcalay, R. N., Prakalapakorn, S. G., Rosenbloom, B. E., Tuason, D. A., & Weinreb, N. J. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109074 · Cited by 17
Bosseboeuf, A., Mennesson, N., Allain‐Maillet, S., Tallet, A., Piver, É., Decaux, O., Moreau, C., Moreau, P., Lehours, P., Mégraud, F., et al. (2020) · Cancers · doi:10.3390/cancers12051254 · Cited by 17
Metadata
- Authors
- Nair, S., Branagan, A. R., Liu, J., Boddupalli, C. S., Mistry, P. K., & Dhodapkar, M. V.
- Affiliations
- Yale Cancer Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-02-11
- Volume
- 374
- Issue
- 6
- Pages
- 555-561
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4804194
- OpenAlex
- W2321709204
- Cited by
- 203
- References
- 26
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 11 · 2023: 22 · 2022: 27 · 2021: 17 · 2020: 26 · 2019: 22 · 2018: 23 · 2017: 17 · 2016: 14
- FWCI
- 24.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (NIAMS 65932)
- National Cancer Institute (R01CA135110, CA 106802, CA135110, R01CA156689, CA156689, R01CA106802, R35CA197603, P30CA016359)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034989)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR065932)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, Gaucher disease, lysolipids, lysophosphatidylcholine, antigen-driven selection, substrate reduction therapy, lipid metabolism, monoclonal gammopathy of undetermined significance, plasma cell dyscrasia
- MeSH terms
- Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Gaucher Disease, Glucosylceramides, Humans, Immunoglobulins, Lysophosphatidylcholines, Multiple Myeloma, Paraproteinemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
